Changes in predictive capacity when adding Ticagrelor and Clopidogrel to an existing allogeneic bloodtransfuion prediction model for cardiac surgery.

Reexamining the impact of dual antiplatelet medication as predictive factor for allogeneic blood transfusion during validation of the TRACK transfusion prediction model in a Dutch adult cardiac surgery population

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON22097

Enrollment

3500

Registered

2021-05-11

Start date

2021-05-12

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease, valvular disease, vascular disease

Interventions

none

Eligibility

Inclusion criteria

Inclusion criteria: • Patients > 18 years • Patients receiving on-pump cardiac surgery. • Patients receiving off-pump cardiac surgery.

Exclusion criteria

Exclusion criteria: A potential patient who meets any of the following criteria will be excluded from participation in the data collection: • Cardiac surgery for congenital disorders

Design outcomes

Primary

Measure	Time frame
How accurately does the TRACK model predict allogeneic blood transfusions in the Amsterdam UMC, location AMC, cardiothoracic surgery population?	—

Secondary

Measure	Time frame
1. How does the predictive capacity of the TRACK model change when the pre-operative use of P2Y12 inhibitors are added as a predictive factor? 2. What is the relationship between pre-operative P2Y12 use and amount and type of blood product transfused 3. Is there a difference in the use of transfusion products between Ticagrelor and other P2Y12 inhibitors, such as Clopidogrel? 4. Is there a difference in length of hospital stay, and the 30/90 day mortality in patients using Ticagrelor, when compared to other P2Y12 inhibitors such as Clopidogrel?	—

Measure

Time frame

1. How does the predictive capacity of the TRACK model change when the pre-operative use of P2Y12 inhibitors are added as a predictive factor? 2. What is the relationship between pre-operative P2Y12 use and amount and type of blood product transfused 3. Is there a difference in the use of transfusion products between Ticagrelor and other P2Y12 inhibitors, such as Clopidogrel? 4. Is there a difference in length of hospital stay, and the 30/90 day mortality in patients using Ticagrelor, when compared to other P2Y12 inhibitors such as Clopidogrel?

—

Contacts

Public ContactRenard Haumann

Amsterdam UMC, Location Amc

r.haumann@amsterdamumc.nl0650051198

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)